Britain and America have finalized a important commercial pact that will ensure zero levies on British pharmaceutical products going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase spending on drugs through the NHS. This pledge secures that tariffs on these vital exports will be held at zero for a period of the next three years.
This agreement is in response to previous threats to dramatically increase import taxes on branded pharmaceutical products, with increases floated as high as 100%.
"This deal with the UK strengthens the global environment for new treatments and brings long-overdue fairness to transatlantic drug exports," an announcement noted.
Trade Significance
Drugs represent one of the UK's largest export categories to the America, which is easily the largest destination for major UK drugmakers.
Statistics indicate that in the year leading up to the third quarter, the UK exported pharmaceutical products valued at billions to the US. This amount accounted for nearly one-fifth of British export trade in that span.
"This guarantee safeguards employment, stimulates funding and paves the way for the UK to become a worldwide center for biotech and pharma," a minister remarked.
Specific British Pledges
The deal involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be limited at 15%. In the past, rebates exceeded 20%.
Recent Tensions
The deal takes place against a ongoing row between the sector and the ministers over spending levels and regulatory access.
These tensions were intensified by claims that US consumers were paying significantly more for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the previous ten-year period.
